Ken Bilchick explains how GLP-1s lower AFib risk and increase survival

New research presented at Heart Rhythm 2026 suggests taking GLP-1 receptor agonists (GLP-1-RAs) may reduce the risk of atrial fibrillation (AFib) and improve survival through mechanisms that extend beyond weight loss alone.

Kenneth Bilchick, MD, MS, director of electrophysiology research and a professor of cardiovascular medicine at the University of Virginia, presented those findings at the conference. He then spoke to Cardiovascular Business for a video interview. 

Bilchick said GLP-1 drugs have an anti-inflammatory effect, which may what led to the lower AFib rates in GLP-1 patients.

The 13,034-patient study matched patients who initiated GLP-1-RA therapy to a similar cohort of more than 385,000 patients who had never received GLP-1-RA therapy and did not have a prior AFib diagnosis. Overall, the GLP-1 group had a significantly better survival rate and a lower risk of AFib. The researchers said this reduction in AFib risk remained consistent, regardless of the level of weight change. There was no difference in these benefits between patients who lost 10% or more of their body weight, less than 10%, and those who gained weight while taking GLP-1s.